Literature DB >> 29986019

Is a Reported Penicillin Allergy Sufficient Grounds to Forgo the Multidimensional Antimicrobial Benefits of β-Lactam Antibiotics?

George Sakoulas1,2, Matthew Geriak1, Victor Nizet2,3.   

Abstract

The majority of patients with reported penicillin allergy are not allergic when tested or challenged. Penicillin allergy testing has been shown to significantly reduce annual healthcare expenditures. Data have emerged showing β-lactams have multidimensional antibacterial effects in vivo, far beyond what is appreciated in standard bacteriological susceptibility testing media. These include enhancing bacterial killing by the innate immune system. Supporting the clinical relevance of these secondary underappreciated effects are recent clinical and pharmacoeconomic analyses that show worse outcomes in patients with reported penicillin allergies who receive non-β-lactam antibiotics when compared to their non-penicillin-allergic counterparts. This is particularly relevant in the treatment of Staphylococcus aureus bacteremia. This article reviews the tremendous advantages offered by β-lactam therapy and makes a strong case that the debunking of false penicillin allergies through a detailed allergy history and penicillin allergy testing should be a vital component of antimicrobial stewardship practices.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29986019      PMCID: PMC6293005          DOI: 10.1093/cid/ciy557

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  82 in total

Review 1.  Staphylococcal manipulation of host immune responses.

Authors:  Vilasack Thammavongsa; Hwan Keun Kim; Dominique Missiakas; Olaf Schneewind
Journal:  Nat Rev Microbiol       Date:  2015-09       Impact factor: 60.633

2.  Penicillin allergy as a public health measure.

Authors:  Roland Solensky
Journal:  J Allergy Clin Immunol       Date:  2013-12-09       Impact factor: 10.793

3.  Critical Role of Alpha-Toxin and Protective Effects of Its Neutralization by a Human Antibody in Acute Bacterial Skin and Skin Structure Infections.

Authors:  Vien T M Le; Christine Tkaczyk; Sally Chau; Renee L Rao; Etyene Castro Dip; Eliane P Pereira-Franchi; Lily Cheng; Sally Lee; Holly Koelkebeck; Jamese J Hilliard; Xiang Qing Yu; Vivekananda Datta; Vien Nguyen; William Weiss; Laszlo Prokai; Terrence O'Day; C Kendall Stover; Bret R Sellman; Binh An Diep
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

4.  Prevalence and characteristics of reported penicillin allergy in an urban outpatient adult population.

Authors:  Stephanie Albin; Shradha Agarwal
Journal:  Allergy Asthma Proc       Date:  2014 Nov-Dec       Impact factor: 2.587

5.  The Impact of a Reported Penicillin Allergy on Surgical Site Infection Risk.

Authors:  Kimberly G Blumenthal; Erin E Ryan; Yu Li; Hang Lee; James L Kuhlen; Erica S Shenoy
Journal:  Clin Infect Dis       Date:  2018-01-18       Impact factor: 9.079

6.  Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.

Authors:  Martin E Stryjewski; Lynda A Szczech; Daniel K Benjamin; Jula K Inrig; Zeina A Kanafani; John J Engemann; Vivian H Chu; Maria J Joyce; L Barth Reller; G Ralph Corey; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2006-12-08       Impact factor: 9.079

7.  Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy.

Authors:  Kamran A Ahmed; Stephanie J Fox; Evangelo Frigas; Miguel A Park
Journal:  Int Arch Allergy Immunol       Date:  2012-04-05       Impact factor: 2.749

8.  The diagnosis and management of anaphylaxis practice parameter: 2010 update.

Authors:  Phillip Lieberman; Richard A Nicklas; John Oppenheimer; Stephen F Kemp; David M Lang; David I Bernstein; Jonathan A Bernstein; A Wesley Burks; Anna M Feldweg; Jordan N Fink; Paul A Greenberger; David B K Golden; John M James; Stephen F Kemp; Dennis K Ledford; Phillip Lieberman; Albert L Sheffer; David I Bernstein; Joann Blessing-Moore; Linda Cox; David A Khan; David Lang; Richard A Nicklas; John Oppenheimer; Jay M Portnoy; Christopher Randolph; Diane E Schuller; Sheldon L Spector; Stephen Tilles; Dana Wallace
Journal:  J Allergy Clin Immunol       Date:  2010-08-07       Impact factor: 10.793

9.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.

Authors:  Sara E Cosgrove; George Sakoulas; Eli N Perencevich; Mitchell J Schwaber; Adolf W Karchmer; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2002-12-13       Impact factor: 9.079

10.  Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.

Authors:  Marin L Schweizer; Jon P Furuno; Anthony D Harris; J Kristie Johnson; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; Sara E Cosgrove; George Sakoulas; Eli N Perencevich
Journal:  BMC Infect Dis       Date:  2011-10-19       Impact factor: 3.090

View more
  10 in total

1.  Reduced Mortality of Staphylococcus aureus Bacteremia in a Retrospective Cohort Study of 2139 Patients: 2007-2015.

Authors:  Eloise D Austin; Sean S Sullivan; Nenad Macesic; Monica Mehta; Benjamin A Miko; Saman Nematollahi; Qiuhu Shi; Franklin D Lowy; Anne-Catrin Uhlemann
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

2.  Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States Veterans Health Care System.

Authors:  Marilyn L Mootz; Rachel S Britt; Allison A Mootz; Grace C Lee; Kelly R Reveles; Kirk E Evoy; Chengwen Teng; Christopher R Frei
Journal:  Hosp Pract (1995)       Date:  2019-10-14

3.  Is the Success of Cefazolin plus Ertapenem in Methicillin-Susceptible Staphylococcus aureus Bacteremia Based on Release of Interleukin-1 Beta?

Authors:  Dan Smelter; Mary Hayney; George Sakoulas; Warren Rose
Journal:  Antimicrob Agents Chemother       Date:  2022-01-03       Impact factor: 5.938

4.  Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.

Authors:  Elias Tannous; Shelly Lipman; Antonella Tonna; Emma Hector; Ziad Hussein; Michal Stein; Sharon Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

5.  Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  Matthew Geriak; Fadi Haddad; Khulood Rizvi; Warren Rose; Ravina Kullar; Kerry LaPlante; Marie Yu; Logan Vasina; Krista Ouellette; Marcus Zervos; Victor Nizet; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

6.  Potential impact of outpatient stewardship interventions on antibiotic exposures of common bacterial pathogens.

Authors:  Christine Tedijanto; Yonatan H Grad; Marc Lipsitch
Journal:  Elife       Date:  2020-02-05       Impact factor: 8.140

Review 7.  Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity.

Authors:  Saira B Chaudhry; Michael P Veve; Jamie L Wagner
Journal:  Pharmacy (Basel)       Date:  2019-07-29

8.  Documented β-Lactam Allergy and Risk for Cesarean Surgical Site Infection.

Authors:  Courtney Johnston; Amy Godecker; Daniel Shirley; Kathleen M Antony
Journal:  Infect Dis Obstet Gynecol       Date:  2022-03-02

9.  Approaching 65 Years: Is It Time to Consider Retirement of Vancomycin for Treating Methicillin-Resistant Staphylococcus aureus Endovascular Infections?

Authors:  Warren Rose; Cecilia Volk; Thomas J Dilworth; George Sakoulas
Journal:  Open Forum Infect Dis       Date:  2022-04-09       Impact factor: 3.835

10.  Antibiotics and Innate Immunity: A Cooperative Effort Toward the Successful Treatment of Infections.

Authors:  Andrew Berti; Warren Rose; Victor Nizet; George Sakoulas
Journal:  Open Forum Infect Dis       Date:  2020-07-20       Impact factor: 3.835

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.